Top Markets
Coin of the day
Relmada Therapeutics, Inc. Relmada Therapeutics, Inc.

Relmada Therapeutics, Inc.

RLMD
Kedudukan dalam Saham #13829
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company... Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
Harga Saham
$4.36
Modal Pasaran
$457.32M
Perubahan (1 hari)
0.69%
Perubahan (1 tahun)
289.29%
Negara
US
Perdagangan Relmada Therapeutics, Inc. (RLMD)

Kategori

EPS untuk Relmada Therapeutics, Inc. (RLMD)
EPS setakat 2026 TTM: 0
Menurut laporan kewangan terkini dan harga saham Relmada Therapeutics, Inc., EPS semasa syarikat (TTM) adalah 0. Pada akhir tahun 2026, syarikat mempunyai EPS sebanyak 0 sama dengan EPS tahun 2026 iaitu 0.
Sejarah EPS untuk Relmada Therapeutics, Inc. dari 2026 hingga 2026
EPS pada akhir setiap tahun
Tahun EPS Ubah
Tidak cukup data untuk tarikh yang disediakan.
EPS untuk syarikat atau pesaing yang serupa
Syarikat EPS Perbezaan EPS Negara
$17.32 -
US
$27.74 -
NL
$-5.29 -
AU
$-7.98 -
US
- -
CH